LRT Capital Management LLC Has $1.59 Million Stock Position in Repligen Corporation $RGEN

LRT Capital Management LLC reduced its position in Repligen Corporation (NASDAQ:RGEN) by 50.5% in the 4th quarter, according to its most recent filing with the SEC. The fund owned 9,709 shares of the biotechnology company’s stock after selling 9,910 shares during the period. Repligen comprises 1.4% of LRT Capital Management LLC’s holdings, making the stock its 27th largest position. LRT Capital Management LLC’s holdings in Repligen were worth $1,591,000 at the end of the most recent quarter.

Several other hedge funds have also recently bought and sold shares of the stock. Entropy Technologies LP lifted its position in Repligen by 97.4% during the fourth quarter. Entropy Technologies LP now owns 5,493 shares of the biotechnology company’s stock worth $900,000 after acquiring an additional 2,710 shares during the last quarter. Avidity Partners Management LP lifted its position in Repligen by 115.9% during the fourth quarter. Avidity Partners Management LP now owns 50,300 shares of the biotechnology company’s stock worth $8,242,000 after acquiring an additional 27,000 shares during the last quarter. Kestra Advisory Services LLC acquired a new stake in Repligen during the fourth quarter worth approximately $150,000. Marshall Wace LLP lifted its position in Repligen by 185.2% during the fourth quarter. Marshall Wace LLP now owns 516,336 shares of the biotechnology company’s stock worth $84,607,000 after acquiring an additional 335,273 shares during the last quarter. Finally, The Manufacturers Life Insurance Company lifted its position in Repligen by 19.4% during the fourth quarter. The Manufacturers Life Insurance Company now owns 57,102 shares of the biotechnology company’s stock worth $9,409,000 after acquiring an additional 9,287 shares during the last quarter. 97.64% of the stock is currently owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

Several equities research analysts have issued reports on RGEN shares. JPMorgan Chase & Co. cut their price objective on shares of Repligen from $180.00 to $165.00 and set an “overweight” rating for the company in a research report on Wednesday, May 6th. Roth Mkm started coverage on shares of Repligen in a research report on Friday, April 17th. They set a “buy” rating and a $160.00 price objective for the company. Wolfe Research started coverage on shares of Repligen in a research report on Tuesday, June 2nd. They set an “outperform” rating and a $145.00 price objective for the company. Wells Fargo & Company cut their price objective on shares of Repligen from $190.00 to $180.00 and set an “overweight” rating for the company in a research report on Wednesday, February 25th. Finally, Canaccord Genuity Group cut their price objective on shares of Repligen from $165.00 to $145.00 and set a “hold” rating for the company in a research report on Monday, April 20th. Two investment analysts have rated the stock with a Strong Buy rating, eleven have given a Buy rating, two have issued a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $164.64.

Repligen Stock Down 2.1%

Shares of RGEN opened at $130.59 on Friday. Repligen Corporation has a 12 month low of $100.99 and a 12 month high of $175.77. The firm’s 50 day moving average is $120.23 and its 200-day moving average is $137.90. The stock has a market capitalization of $7.37 billion, a PE ratio of 145.10, a P/E/G ratio of 2.51 and a beta of 1.09. The company has a current ratio of 9.20, a quick ratio of 7.78 and a debt-to-equity ratio of 0.26.

Repligen (NASDAQ:RGEN) last announced its earnings results on Tuesday, May 5th. The biotechnology company reported $0.48 EPS for the quarter, topping the consensus estimate of $0.38 by $0.10. Repligen had a net margin of 6.73% and a return on equity of 4.88%. The company had revenue of $194.26 million for the quarter, compared to analysts’ expectations of $192.05 million. During the same period last year, the firm earned $0.39 earnings per share. The business’s revenue for the quarter was up 14.8% on a year-over-year basis. Repligen has set its FY 2026 guidance at 1.970-2.050 EPS. Equities research analysts forecast that Repligen Corporation will post 1.99 EPS for the current year.

Repligen Profile

Repligen Corporation (NASDAQ:RGEN) is a life sciences company that develops and manufactures high-value consumable products for bioprocessing applications. Founded in 1981 and headquartered in Waltham, Massachusetts, the company specializes in technologies that support the development and production of biopharmaceuticals. Repligen’s offerings include chromatography resins, filtration membranes, single-use technologies and systems for downstream purification and upstream processing.

The company’s core product lines encompass Protein A affinity resins, designed for monoclonal antibody purification, and a portfolio of ion exchange, multimodal and hydrophobic interaction resins.